Cancer cell · 2026
A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gudenas Brian L, Ahmad Shiekh Tanveer, Englinger Bernhard, Liu Anthony P Y, Zhao Miao, Paul Leena, Hadley Jennifer, Li Yiran, Batts Melissa, Mittal Priya, Wu Stephanie C, Lewis Sara A, Han Katie, Soliman Taha, Lin Hong, Janke Laure, Meredith David, Pfaff Elke, Gojo Johannes, Cotter Jennifer, Klimo Paul, Boop Frederick A, Gajjar Amar, Robinson Giles W, Rosén Gabriela, Alexandrescu Sanda, Jones David T W, Orr Brent A, Swartling Fredrik J, Filbin Mariella G, Northcott Paul A
Аннотация
Pineoblastoma is a clinically aggressive childhood brain tumor composed of distinct molecular subgroups with divergent driver genes, demographics, and clinical outcomes. To identify developmental origins and mechanisms governing disease pathogenesis, we derive single-cell transcriptomes from pineal parenchymal tumors, aligning malignant cells with developmental counterparts to retrace cellular origins. Integrative computational analyses map pineoblastoma origins to transient, cycling pinealocyte progenitors during development. Lineage-specific perturbation of suspected drivers in the early pineal gland yields preclinical models representative of consensus molecular subgroups. Multi-omic characterization of patient tumors and these models uncover a tumor-associated photoreceptor signature (TAPS) common to pineoblastoma, retinoblastoma, and Group 3 medulloblastoma. Transcriptional activity of this signature within respective cellular origins establishes a developmental basis for molecular similarities between entities. Photoreceptor signature constituents are selective dependencies across these anatomically distinct central nervous system malignancies, motivating future studies evaluating developmentally encoded programs of malignancy as potential therapeutic liabilities.